Scilex Holding Company ( (SCLX) ) has shared an announcement.
On April 11, 2025, Scilex Holding Company announced a 1-for-35 reverse stock split of its common stock, effective April 15, 2025, to regain compliance with Nasdaq’s minimum bid price requirement. The reverse split will reduce the number of outstanding shares from approximately 243 million to 6.9 million, and no fractional shares will be issued, with cash payments provided instead. The move, approved by stockholders on March 19, 2025, aims to stabilize Scilex’s market position and ensure continued listing on the Nasdaq Capital Market.
More about Scilex Holding Company
Scilex Holding Company is a revenue-generating company based in Palo Alto, California, focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain. The company targets high unmet needs and large market opportunities with non-opioid therapies and has commercial products like ZTlido, ELYXYB, and Gloperba. Scilex is also developing product candidates such as SP-102, SP-103, and SP-104, which are in various stages of clinical trials.
YTD Price Performance: -43.41%
Average Trading Volume: 1,378,503
Technical Sentiment Signal: Strong Buy
Current Market Cap: $57.67M
Learn more about SCLX stock on TipRanks’ Stock Analysis page.